Related Experiment Video
Updated: Nov 11, 2025
10:28
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
5.5K
Colchicine in coronary artery disease.
1Department of Medicine, Salford Royal NHS Foundation Trust, Salford, UK arnavkatira@gmail.com.
Postgraduate Medical Journal
|March 30, 2021
Summary
Colchicine, an anti-inflammatory drug, may help prevent cardiovascular events in patients with coronary artery disease (CAD). Studies suggest it reduces myocardial infarction and other major adverse cardiovascular outcomes in both stable and unstable CAD.
Area of Science:
- Cardiology
- Pharmacology
- Inflammation Research
Background:
- Coronary artery disease (CAD) is a leading global cause of death.
- Inflammation is a critical factor in atherosclerosis and CAD.
- Elevated C-reactive protein indicates a poor prognosis in CAD patients.
Purpose of the Study:
- To explore the therapeutic potential of colchicine in managing stable and post-acute coronary syndrome (ACS) patients.
- To evaluate colchicine's role as an anti-inflammatory agent in cardiovascular disease prevention.
Main Methods:
- Review of existing literature on colchicine's anti-inflammatory properties.
- Analysis of clinical data regarding colchicine use in patients with stable CAD and post-ACS.
- Discussion of colchicine's impact on cardiovascular outcomes.
Main Results:
- Colchicine exhibits significant anti-inflammatory effects.
- The drug is associated with a reduced incidence of myocardial infarction in CAD patients.
- Colchicine may decrease major adverse cardiovascular events in both stable and unstable CAD.
Conclusions:
- Colchicine is an inexpensive and effective anti-inflammatory medication.
- Colchicine shows promise in preventing cardiovascular events in patients with stable and unstable CAD.
- Further research into colchicine's role in cardiovascular disease management is warranted.
Related Concept Videos
01:10Drugs that Destabilize Microtubules
2.2K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.2K
01:27Coronary Artery Disease V: Interprofessional Care
107
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
107
01:26Coronary Artery Disease IV: Preventive Measures
453
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
453
01:30Coronary Artery Disease I: Introduction
615
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
615
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
895
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
895
01:26Coronary Artery Disease II: Pathophysiology
155
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
155